EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> E-Therapeutics (ETX) struck agreements with Intellegens and Biorelate to access artificial intelligence tools. Pilot studies suggest the tools complement ETX’s computational drug discovery technology. Statement

> ValiRx presented an analysis of data from a phase 2 trial of cancer candidate VAL401. Release 

> Avacta and Glythera entered into a licensing agreement. The signing of the deal follows an initial study to evaluate the use of Avacta's Affimer technology with Glythera's conjugation chemistry. Statement

> British trade group The BioIndustry Association secured clearance to intervene in a Supreme Court patent case. The BIA is concerned the court’s ruling could affect how much data and evidence companies need to patent inventions. Release

> Transgene’s China joint venture dosed the first hepatitis B patient in a phase 1 trial. Statement

> TxCell snagged a government loan to support preclinical development of its lead CAR-Treg program. Release